AI tools for breast cancer detection fall short of radiologists' expectations
Half of radiologists use FDA-approved AI tools for cancer detection. Nearly all are disappointed.
Why it matters
AI deployment in high-stakes medical imaging is underperforming against pre-adoption hype. This shapes how practitioners budget, evaluate, and roll out AI tools in regulated clinical settings — and signals a gap between vendor claims and field reality.
The key facts
9 to know50% of 215 Society of Breast Imaging members surveyed use FDA-approved AI tools for breast cancer detection
Only 35% report lower recall rates vs. 59% who expected them
Gap between promise and reality spans all measured categories
Survey conducted among radiologists (practicing professionals, not labs)
215 Society of Breast Imaging members surveyed
~50% already deploy FDA-approved AI tools for breast cancer detection
35% report lower recall rates achieved (vs. 59% expected)
Gap exists across all measured categories
Performance vs. promise mismatch in a regulated, safety-critical domain
Go to the source
The Decoderthe-decoder.com
Publisher excerpt: About half of 215 surveyed members of the Society of Breast Imaging already use FDA-approved AI tools for breast cancer detection, but the results fall short of expectations. Only 35 percent report lower recall rates, while 59 percent had expected them. The gap between promise and reality runs…